HPV Newsletters

Insight HPV for OB/GYNs - Spring 2005

Issue Date: March 25, 2005    Expires: March 25, 2008

Don't miss the premiere issue of Insight HPV, a CME-certified newsletter developed for obstetricians, gynecologists, and OBGYN nurses. In part one of this four-part series, three prominent OBGYNs present the epidemiology, risk factors and persistence of HPV.

This program is designated for a maximum of 0.5 credits in category 1 of the Physician's Recognition Award of the American Medical Association.

Release Date: March 25, 2005
Expiration Date: March 25, 2008

Learning Objectives

After reading this publication, the participant should be able to:

• Describe the epidemiology of HPV and its association with genital warts and cervical cancer.
• Identify high-risk and low-risk HPV types and their associated clinical manifestations.
• Recognize behavioral and/or other risk factors that infl uence the incidence or progression of HPV infection.

Faculty

Jeffrey Lin, MD, FACOG

Associate Professor Director, Divisions of Gynecologic Oncology and General Obstetrics and Gynecology Chief, Gynecologic Surgery The George Washington University Medical Center Washington, DC
Disclosures: Dr. Lin has no potential conflicts of interest to disclose.

J.Thomas Cox, MD

Director of the Gynecology and Colposcopy Clinic University of California, Santa Barbara
Past Executive Medical Director National HPV and Cervical Cancer Prevention Resource Center, American Social Health Association Raleigh-Durham, NC
Disclosures: Dr. Cox participates in speakers' bureaus for Digene and 3M Pharmaceuticals. He also serves as a consultant to Digene and 3M Pharmaceuticals. Dr. Cox serves on the data and safety monitoring board for Merck & Co.'s worldwide quadravalent HPV vaccine.

Stanley Gall, MD

Donald E. Baxter Professor and Chairman Emeritus Department of Obstetrics and Gynecology University of Louisville Health Sciences Center Louisville, KY
Disclosures: Dr. Gall has received grant/research support from and served as a consultant to Merck & Co., GlaxoSmithKline, and 3M Pharmaceuticals. Dr. Gall has participated in speakers' bureaus for Merck & Co., 3M Pharmaceuticals and Pfizer and has served on an advisory board for Merck & Co. and GlaxoSmithKline.

About this CME Activity

Please read the publication, reflection on its content, complete the CME Self-Assessment and CME Evaluation and return them to the address indicated. Upon receipt, your certificate of completion will be sent to you with the correct answers to the CME Self-Assessment. The estimated time a leaner will need to complete this self study activity is .5 hours.